Immunoglobulin replacement therapy is associated with reductions in hypogammaglobulinaemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukaemia or non-Hodgkin’s lymphoma, according to a study in Blood Advances.

Dr Jacob D Soumerai, from the Massachusetts General Hospital Cancer Center in Boston, and colleagues examined patterns of immunoglobulin G (IgG) testing and the effectiveness of immunoglobulin replacement therapy in patients with chronic lymphocytic leukaemia (CLL) or non-Hodgkin’s lymphoma (NHL) in a retrospective, longitudinal study.

IgG testing, infections, and antimicrobial use were compared before with three, six, and 12 months after therapy initiation.

The study population included 17,192 patients: 3960 with CLL and 13,232 with NHL.